# rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics

> **NCT02356419** · PHASE1 · UNKNOWN · sponsor: **Shenyang Sunshine Pharmaceutical Co., LTD.** · enrollment: 40 (estimated)

## Conditions studied

- Chronic Renal Failure

## Interventions

- **DRUG:** Recombinant erythropoietin stimulating protein

## Key facts

- **NCT ID:** NCT02356419
- **Lead sponsor:** Shenyang Sunshine Pharmaceutical Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-09
- **Primary completion:** 2015-01
- **Final completion:** 2015-03
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2015-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02356419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02356419, "rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02356419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*